jkids210,
It is obvious by your inquiries both here and other places that this company intrigues you. To you, I suppose, it is either a diamond in the rough, awaiting it's explosion onto the marketplace after 7 long years; or it is an entity in it's final throes that just didn't die when it was a couple years old. Some would say, (including our local naysayer and bio-medically-uneducated Stockboy)that the principals of this company are theives and are just sucking all the blood out of it. You will get the same response from the super-intelligent Frogdreaming.
It says in your profile that you are an investor in Biomedical companies and that you like to watch small companies with undervalued potential. It seems you work in the business management and financial world. Therefore you yourself may have the best chance at evaluating DNAPrint's future and potential.
Keeping in mind that DNAPrint came into the scene at the end of the dot-com craze and that the biotech sector has been in limbo for several years, this fledgling company is in a category you are familiar with; one that takes years to develop successful biomedical research that leads to product
efficacy and marketing, not to mention pharmeceutical applications that take kazillions of dollars and years upon years of FDA process and testing.
I myself have never had a problem with the management or administration of this company. Suffice it to say that I have been an officer of several companies in a very difficult industry after 40 years of management. I knew from the start that DNAPrint was not going to be the instant speculative buy that this OTC-BB has a plethora of.
On one hand, DNAPrint can easily be a disappointment to all who have invested over the 7 years and have seen the value of their original pink-sheet baby dwindle with a reverse and little revenue.
On the other hand, and this is just personal opinion, it is amazing to me that this company has survived past the deadly 5 year mark in an almost impossible sector, not exactly a break-into-and-survive environment, and found ways to sell what technology it does have while continuing research and development towards several projects, along with a very healthy relationship with the FDA.
You eyes should be on Hector Gomez. Get to know him a little better. His relationship with Merck. Also, don't fall into the trap of looking at this stock through blue-chip glasses. After all, it is one half of a penny a share.
Good luck.
AI
